Heparin for prophylaxis of venous thromboembolism in intracerebral haemorrhage.
Maximilian I SprügelJochen A SembillJoji B KuramatsuStefan T GernerManuel HagenSebastian S RoederMatthias EndresKarl Georg HaeuslerJan SobeskyJohannes SchurigSarah ZweynertMiriam BauerPeter VajkoczyPeter Arthur RinglebJan Christoph PurruckerTimolaos RizosJens VolkmannWolfgang MuellgesPeter KraftAnna-Lena SchubertFrank ErbguthMartin NueckelPeter D SchellingerJörg GlahnUlrich J KnappeGereon Rudolf FinkChristian DohmenHenning StetefeldAnna Lena FisseJens MinnerupGeorg HagemannFlorian RakersHeinz ReichmannHauke SchneiderSigrid WöpkingAlbert C LudolphSebastian StösserHermann NeugebauerJoachim RötherPeter MichelsMichael SchwarzGernot ReimannHansjörg BäznerHenning SchwertJoseph ClassenDominik MichalskiArmin GrauFrederick PalmChristian UrbanekJohannes C WöhrleFahid AlshammariMarkus HornDirk BahnerOtto W WitteAlbrecht GuentherGerhard F HamannHannes LückingArnd DörflerStefan SchwabHagen B HuttnerPublished in: Journal of neurology, neurosurgery, and psychiatry (2019)
Heparin administration for venous thromboembolism (VTE) prophylaxis in patients with ICH appears to be safe regarding IHC among non-OAC-ICH, VKA-ICH and NOAC-ICH in this observational cohort analysis. Randomised controlled trials are needed to verify the safety and efficacy of heparin compared with other methods for VTE prevention.